Preventing Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
Lead Physician: Sherman Tang, MD, Memorial Hermann Southwest
A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillatio
Sponsor: Johnson & Johnson Pharmaceutical Research & Development
Initiation Date: 2007-12-13
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713.456.4011 or Kristin Chandler, RN, CCRP, at 713.456.4073.